Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study
Conclusions Tamoxifen did not show any OS advantage in Egyptian patients with advanced HCC. Use of this drug is discouraged.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research
More News: Alcoholism | Cancer | Cancer & Oncology | Carcinoma | Children | Egypt Health | Hepatitis | Hepatitis B | Study | Tamoxifen